>> I would also say that the cost of Sub IQ would certainly make the insurance co's and dr's who think about such things, prefer the sub q. <<
In my previous post I was talking about malpractice insurance rather than insurance for patient reimbursement. But your point about cost is valid –HMO’s and third-party payers would like the idea of minimizing office visits.
Since we agree that the subcutaneous route for Squalamine is at best pretty far out in the future, the question remains: why did Dr. Levitt bring this up at the R&R talk? More important, why did he spend so much time talking about the 10mg dose and voluntarily showing the 10mg-visual-acuity data on slide #12 that was not exactly stellar?
Market Data 
Markets 
AI
